Ficoll-Paque™ versus Lymphoprep™: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations Myocardial infarction is the leading cause of congestive heart failure and death in developed countries [1] . An estimated 10 million people in Europe alone suffer with heart failure [2] and this number is set to increase over the coming decades. Experimental evidence suggests that bone marrow-derived stem/progenitor cells may contribute to the regeneration of infarcted myocardium and could result in recovery of cardiac function [3] .
Several clinical studies have been performed involving the transfer of the autologous bone marrow mononuclear cell (BM-MNC) fraction to the damaged myocardium of patients following acute myocardial infarction [4] [5] [6] [7] [8] with conflicting results. Whereas the Autologous Stem Cell Transplantation in Acute Myocardial Infarction (ASTAMI) trial found no demonstrable improvement in left ventricular systolic function of the cell-treated group over the control group [5] , the Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) study associated intracoronary infusion of autologous BM-MNCs with improved recovery of left ventricular contractile function [6] .
Isolation of the BM-MNC fraction from whole bone marrow [9] requires a density gradient medium, a polysaccharide solution of a specific density, which acts as a liquid filter to remove undesired components (i.e., red blood cells [RBCs] , platelets and granulocytes) while retaining BM-MNCs. The BM-MNC fraction contains a heterogeneous population of cell types including hematopoietic stem cells + positivity. Despite current evidence of cardiac improvement following reinfusion of BM-MNCs in various clinical trials [10] and animal experiments [11] , it is still unclear which of the cell type(s) within this fraction is responsible for the effect. Several mechanisms have been suggested, including in situ transdifferentiation of transplanted cells into cardiomyocytes, neoangiogenesis and paracrine effects. The role of HSCs and Aims: Contradictory outcomes from recent clinical trials investigating the transplantation of autologous bone marrow mononuclear cell (BM-MNC) fraction containing stem/progenitor cells to damaged myocardium, following acute myocardial infarction, may be, in part, due to the different cell isolation protocols used. We compared total BM-MNC numbers and its cellular subsets obtained following isolation using Ficoll-Paque™ and Lymphoprep™ -two different density gradient media used in the clinical trials. Materials & methods: Bone marrow samples were taken from patients entered into the REGENERATE-IHD clinical trial after 5 days of subcutaneous granulocyte colony-stimulating factor injections. Each sample was divided equally for BM-MNC isolation using Ficoll-Paque and Lymphoprep, keeping all other procedural steps constant. Isolated fractions were characterized for hematopoietic stem cells, endothelial progenitor cells, T lymphocytes, B lymphocytes and NK cells using cell surface markers CD34 + , CD133 + VEGFR2 + , CD45 + CD3 + , CD45 + CD19 + and CD45 + CD16 + CD56 + , respectively. There were no significant differences in the absolute numbers and percentage cell recovery of various mononuclear cell types recovered following separation using either density gradient media. Cell viability and the proportion of various cell phenotypes investigated were similar between the two media. They were also equally efficient in excluding unwanted red blood cells, granulocytes and platelets from the final cell products. Conclusion: We demonstrated that the composition and quantity of cell types found within therapeutic BM-MNC preparations for use in clinical trials of cardiac stem cell transplantation are not influenced by the type of density gradient media used when comparing Ficoll-Paque and Lymphoprep.
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EPCs in these mechanisms is being explored in numerous studies. However, much less is known about the contribution of other BM-MNC cell types, such as lymphocytes, to the regenerative process. For example, lymphocytes produce TNF-a, which upregulates vessel-wall expression of VCAM-1 [12] , which is required for homing of stem/progenitor cells to injured tissue via very late antigen-4 [13] .
It has been suggested that the contradictory outcomes from the clinical trials may partly be due to the cell isolation protocols used [14] , with different density gradient media giving different cell yields. Here, we sought to compare the two different media used in the clinical trials (FicollPaque™ vs Lymphoprep™) to test whether, in addition to total BM-MNC number, there are significant differences in cellular subsets within this fraction obtained after isolation.
Materials & methods n Study population
Bone marrow samples were obtained from patients entered into the Randomized Control Trial to Compare the Effects of G-CSF and Autologous Bone Marrow Progenitor Cells Infusion on Quality of Life and Left Ventricular Function in Patients with Heart Failure Secondary to Ischemic Heart Disease (REGENERATE-IHD) clinical trial and used for further in vitro ana lysis. In brief, this trial is designed to determine whether autologous bone marrow-derived stem/progenitor cells improve cardiac function and symptoms in patients with established heart failure. Patients included in the trial have a history of ischemic heart disease with resulting symptomatic heart failure (New York Heart Association class II-IV), despite optimal medical therapy with no further treatment options. Patients undergo a bone marrow aspiration following 5 days of granulocyte colony-stimulating factor mobilization treatment. The clinical trial was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient. Bone marrow aspirations from 14 patients were used for this study.
n Bone marrow harvest Following written consent, patients were rolled into a left lateral position and the posterior superior iliac spine was identified. The overlying area was cleaned thoroughly with Hydrex Pink (pink chlorhexadine gluconate 0.5% w/v in 70% v/v DEB, Ecolab Ltd, UK). A total of 10 ml of 2% lidocaine hydrochloride injection BP (2% w/v 20 mg in 1 ml) was infiltrated into the skin puncture site. A 15-gauge bone marrow aspiration needle (Sternum Temno, Allegiance Healthcare Corporation, USA) was introduced at 90° to the bone surface. A total of 5 ml of bone marrow was aspirated into a 10 ml LuerLok syringe containing 1 ml heparin sodium (20,000 IU in 20 ml, LEO Laboratories Ltd, UK). After each aspiration, the bone marrow needle was either rotated clockwise 180° or advanced further into the marrow cavity to ensure a new reservoir of bone marrow was accessed. A single bone puncture site yielded three to four sets of bone marrow aspirate before the needle was removed and introduced into a new site. A total of 50 ml of bone marrow was aspirated equally into 10 × 10 ml heparintreated syringes from three separate sites over the right iliac crest. The bone marrow aspirates were then kept at room temperature whilst awaiting transfer to the stem cell laboratory.
n Isolation of BM-MNCs
Bone marrow aspirates from the heparintreated syringes were pooled into a single transfusion bag (Baxter, IL, USA). The entire volume (50 ml) was passed through a blood component transfusion set with a 200 µm filter (Baxter SA, Lessines, Belgium). A total of 25 ml of this volume was then layered on 25 ml of Ficoll-Paque (density gradient: 1.077 ± 0.001 g/ml, GE Healthcare, Uppsala, Sweden) and the remaining 25 ml of bone marrow layered on 25 ml of Lymphoprep (density gradient: 1.077 ± 0.001 g/ml, Axis-Shield, Oslo, Norway). Both preparations were centrifuged in a Sorvall RT Legend centrifuge (Thermo Fisher Scientific, Leicestershire, UK) at 2500 rpm for 30 min with the brake off. The BM-MNC layer from each preparation was extracted and spun again at 2500 rpm for 10 min with the brake off. The resulting cell pellets were resuspended and underwent two cycles of washing in 0.9% saline (Baxter, Norfolk, UK). The final cell pellets were resuspended in 2 ml autologous serum. Serum was obtained from 6 × 7 ml plain red-top vacutainers (BD, Plymouth, UK) of peripheral blood, which had been allowed to clot and centrifuged in a Sorvall RT Legend centrifuge (Thermo Fisher Scientific) at 2500 rpm for 5 min to yield autologous serum. Each cell suspension was passed through a 100 µm filter (BD Biosciences, MA, USA), which was rinsed through with 0.5 ml autologous serum. A total of 250 µl was extracted from each final cell suspension for this ana lysis. The total white blood cell (WBC) count and BM-MNC count were derived from data obtained by full blood count ana lysis of the final cell suspensions using a LH750 Beckman 
Results
Results were obtained from bone marrow aspirates from 14 patients; however, owing to logistical reasons, not all samples received the complete range of cellular analyses. + subpopulations within the BM-MNC fraction as they have previously been implicated in myocardial repair. Our results demonstrate that the proportion of CD34 + subpopulation in BM-MNCs is similar between the two density gradient media used (p = 0.81). However, there was a nonsignificant increased proportion of EPCs present in BM-MNCs separated using Ficoll-Paque (p = 0.05). n Viability ana lysis A total of 12 sets of bone marrow aspirates underwent viability assessment via 7AAD staining as part of EPC enumeration. The mean viability after Lymphoprep preparation was 95.9 ± 3.8% compared with 94.9 ± 4.6% using Ficoll-Paque preparation (Figure 4) . This difference was not statistically significant (p = 0.12).
Discussion
Our study demonstrates that there is no difference in the absolute numbers and percentage of cell recovery for various mononuclear cell types recovered after processing of bone marrow using Ficoll-Paque or Lymphoprep. In addition, the proportion of various cell phenotypes investigated within the BM-MNC fraction was not significantly different between separation by Ficoll-Paque or Lymphoprep. The two density media are also equally efficient at excluding unrequired RBCs, granulocytes and platelets from the final cell products. Cell viability obtained following processing was not influenced by the type of density gradient media used either.
However, we observed a trend for higher absolute EPC counts and EPC:BM-MNC ratio using Ficoll-Paque separation. EPC enumeration via flow cytometry is an inherent rare-event ana lysis. 
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The total number of EPCs is calculated indirectly using flow cytometric beads of a known concentration. Therefore, differences between relatively rare cell events recorded can become artificially amplified when calculating absolute cell numbers. This could account for the apparent skewing of the Ficoll-Paque EPC data shown in Figure 2C and subsequent raised EPC:BM-MNC ratio, which could explain the trends observed. As such, these results should be considered with caution. It is not unexpected that our ana lysis has demonstrated that Ficoll-Paque and Lymphoprep are equally effective in isolating BM-MNCs. A comparison of the two density gradient media based on the manufacturer's data provided revealed that both consist of a polysaccharide solution of 5.7% (w/v) with a density of 1.077 ± 0.001 g/ml. However, although both also include sodium diatrizoate, Lymphoprep with 9.1% (w/v) contains 0.1% more of the compound than Ficoll-Paque, which has 9 g of sodium diatrizoate per 100 ml.
Although this difference appears minimal, it is unknown whether such a negligible amount would have an effect on the ability of the media to isolate cells. Another distinguishing feature is that FicollPaque contains 0.0231 g of disodium calcium EDTA per 100 ml, while Lymphoprep does not contain any of this anticoagulant. It is conceivable that the additional anticoagulant effect of EDTA within Ficoll-Paque could improve cell yield following processing owing to a decreased risk of clotting and subsequent encapsulating of the cells within those clots. However, our results indicate that this effect is unlikely to have occurred.
The two largest randomized controlled clinical trials published to date on the use of bone marrow stem/progenitor cells in cardiac repair following acute myocardial infarction have reported conflicting outcomes despite similar trial design and patient characteristics. The REPAIR-AMI trial involving 204 patients investigated the effect of intracoronary infusion of autologous BM-MNCs 3-7 days after reperfusion therapy for acute myocardial infarction [6] . It demonstrated a significant increase in global left ventricular ejection fraction of 5.5% in cell-treated patients compared with 3.0% in placebo-treated patients. On the other hand, patients who received intracoronary autologous BM-MNC infusion had no significant improvement in left ventricular function compared with the nontreated control group in the ASTAMI trial [5] . It has been proposed that the different bone marrow-derived stem/progenitor cell isolation protocols used in these studies may account for the contrasting results [14] . The ana lysis performed by Seeger et al. included a direct comparison between these protocolsFicoll-Paque in REPAIR-AMI and Lymphoprep in ASTAMI -and concluded that a significantly higher number of BM-MNCs were obtained using the Ficoll-Paque protocol in REPAIR-AMI as compared with that obtained using the Lymphoprep protocol in ASTAMI. It is important to note that other than the type of density medium used, there were many other key processing steps which differed between the two protocols. These include washing procedures, washing media and cell reconstitution media used and overnight storage conditions -factors that may all affect cell number, viability and functionality.
Our study has demonstrated that the type of density media used is unlikely to cause the differences in cell numbers observed by Seeger et al., and therefore may not account for the contradictory outcomes in the clinical trials. Further investigations should therefore focus on examining each of the other key procedural steps in the protocol systematically to identify the main factors influencing cell numbers obtained. This may be an extremely important factor in clinical trials involving the use of stem cells in any organ/ tissue regeneration should a positive outcome be, in part, due to a dose-dependant response. In ReseaRch aRticle Yeo, Saunders, Locca et al.
addition, ana lysis of any effect on cell function by each of these procedural steps would also be desirable as this is an important factor in stem cell regenerative capability. As the exact cell type or combination of cell types within the BM-MNC fraction responsible for cardiac functional improvement has not been fully elucidated, it is essential that cell isolation using different types of density gradient media does not affect the number and proportion of various cellular components within the BM-MNC fraction obtained. Our results clearly demonstrate that no such differences are observed between Lymphoprep or Ficoll-Paque and therefore it is safe to assume that either density gradient media would be equally effective when used in clinical trials provided similar protocols are used.
Conclusion
In conclusion, we demonstrated that in the case of Lymphoprep and Ficoll-Paque, the type of density gradient media used in the isolation of the BM-MNC fraction for use in clinical trials does not affect the composition and quantity of cell types found within. 
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Executive summary
Clinical trials investigating the transplantation of autologous bone marrow-derived mononuclear cell fraction to injured myocardium following acute myocardial infarction have reported conflicting results. Different cell isolation protocols for processing bone marrow may account for this difference. We compared the effects of two different types of density gradient media, Lymphoprep™ and Ficoll-Paque™, used in the clinical trials on bone marrow-derived mononuclear cells obtained. Cellular composition and cell numbers within the bone marrow-derived mononuclear cell fraction is not significantly different. Further studies should examine other cell isolation procedural steps to identify the main factors influencing quality and quantity of cell yield. 
